Khorshidi et al., JMM Case Reports 2018;5
DOI 10.1099/jmmcr.0.005133

A case report of brain abscess caused by *Nocardia cyriacigeorgica* in a diabetic patient

Mehdi Khorshidi,1 Sepehr Navid,1 Davood Azadi,1 Dariush Shokri1,2 and Hasan Shojaei1,*

**Abstract**

**Introduction.** *Nocardia* are Gram-positive partially acid-fast bacilli capable of inducing a wide range of infections in patients with immunodeficiency, AIDS, cancer, lupus erythematosus and diabetes. *Nocardia cyriacigeorgica* was first isolated in 2001 from a patient with chronic bronchitis. Since then, there have been reports on the clinical significance of this organism in patients with bronchitis, brain abscess and lung diseases. We, herein, report a case of brain abscess in an elderly diabetic patient from Iran.

**Case presentation.** The patient was a 73 year-old woman admitted to hospital due to severe headache and shortness of breath. The patient had lived with diabetes for 20 years and suffered from chronic foot ulcer. She was admitted to hospital with fever, weakness, drowsiness and vomiting. Clinical examination and the head CT scan of the left frontal lobe of the brain revealed a metastatic carcinoma involving skull bone in the tumor that resulted in two surgical operations in the following two years. The brain abscess biopsy revealed an infection with *Nocardia cyriacigeorgica* confirmed by phenotypic and molecular tests including a PCR-based amplification of a target genetic marker, a 596 bp fragment of 16S rRNA gene, followed by almost full 16S rRNA sequencing.

**Conclusion.** The rare infections, such as brain abscess with *Nocardia*, are easily neglected or misdiagnosed due to the fastidious nature of the organism and inadequate microbiological experience of laboratories in the hospitals of developing countries. This case shows that hospitals should consider a better laboratory protocol to deal with the clinical cases in which fastidious organisms, and in particular *Nocardia*, are involved.

**INTRODUCTION**

*Nocardia* was first described by Nocard in 1888 as a fungus but was later classified as an aerobic bacterium and member of the genus *Nocardia*, and order *Actinomycetales* [1]. *Nocardia cyriacigeorgica* is a Gram-positive, non-motile, spore-less, aerobic, partially acid-fast bacillus that is a member of the actinomycetes. It was first isolated by Yasin et al. in 2001 from a chronic bronchitis patient [2]. This bacterium could be mainly found in soil but it can also live in still water and enter the human body through dust respiration and traumatic inoculation and give rise to infections such as lung infection, sepsis, chronic bronchitis and brain abscess [3–7]. Patients with immunodeficiency, AIDS, cancer and diabetes, connective tissue disorders, and those who receive transplants or immunosuppressive drugs are among the main hosts of *Nocardia* infections [7]. However, isolated cases have been reported in immunocompetent hosts [8–11].

Microbiological isolation and identification of *Nocardia* from clinical samples by the conventional methods in general hospital laboratories are difficult. Molecular methods have proven to be highly discriminatory. These methods are currently in use in research and the reference laboratories as evidenced in the literature on *Nocardia* [12, 13]. The potential for incorporation of molecular techniques in clinical microbiology for quicker and more accurate species identification is fundamental for determination of treatment plans and prediction of antimicrobial sensitivity [12].

**Patient history**

The patient was a 73-year-old woman admitted to hospital in May 2015 due to severe headache and shortness of breath. The patient suffered from diabetic foot ulcer, fever and vomiting at the time of hospitalization. She also had deep venous thrombosis (DVT) in the lower extremities. The lower respiratory tract infection was not confirmed by chest X-ray on her first hospital admission. The patient was
initially suspected to have central nervous system (CNS) infection, and in the course of her treatment additional diagnosis of brain abscess was made and ultimately diagnosis of metastatic carcinoma was also histologically confirmed. The laboratory information of the patient is listed in Table 1. The medical examination and computed tomography (CT) detected a metastatic carcinoma involving skull bone in the tumor. In microscopic examination of the cerebral mass, neoplastic proliferation of epithelial cells was observed as cellular plates. Most cells were hyperchromatic.

**METHODS**

After the first surgery, in addition to general laboratory tests, brain biopsy and pathological examination of the presenting lesion was undertaken by the hospital general laboratory. The biopsy was investigated by direct microscopy test.

In the second surgery isolates from the diabetic foot ulcer and the brain biopsy taken from the patient were investigated by our research laboratory. The foot ulcer isolates were identified by culture and phenotypic features and the isolate from the brain biopsy was identified by conventional microbiological tests that included direct smear analysis by Gram and partial acid-fast staining, culture on blood agar and Sauton’s agar and incubation at 37 and 45 °C. The biochemical assays used to identify the isolate included casein, tyrosine, xanthine, gelatin, aesculin and adenine degradations and urease and citrate production. The drug sensitivity of the isolate was evaluated by the broth microdilution method, based on criteria indicated in CLSI M24-A2 [14]. The molecular identification of the isolate included the PCR-based amplification of a target genetic marker i.e. a 596 bp fragment of the 16S rRNA gene as recommended by Laurent et al. [15] confirming the identity of the organism at the genus level followed by 16S rRNA sequencing for definitive identification at the species level [16].

**RESULTS**

After the first brain surgery the brain biopsy was examined by the hospital laboratory and, based on the results from direct microscopy tests, *Candida* sp. was reported. After the second surgery the clinical samples investigated by our research laboratory. *Staphylococcus aureus* and *Escherichia coli* were isolated from the foot ulcer and confirmed by conventional microbiological tests. The results of the brain biopsy investigation by microbiological tests revealed growth of chalky bacterial colonies with a soil aroma on culture media (Fig. 2). The Gram and partial acid-fast staining of the colonies indicated Gram-positive rods with branched filaments resembling species of the genus *Nocardia* (Fig. 2). The organism was able to grow at 37 and 45 °C and was positive for catalase production, aesculin hydrolysis and sucrose fermentation and was negative for casein, tyrosine, citrate, xanthine, gelatin and urease assays. The antibiotic sensitivity test showed that the isolate was sensitive to trimethoprim–sulfamethoxazole, doxycycline, amikacin, ciprofloxacin, penicillin G and metronidazole, had intermediate resistance to ceftriaxone and erythromycin and was resistant to imipenem and vancomycin.

The PCR amplification of a genetic marker based on a 596 bp region of the 16S rRNA confirmed the identity of the isolate as a member of the genus *Nocardia*. The 16S rRNA gene sequence of the isolate (937 base pairs) showed 100 % similarities with the corresponding sequence of *Nocardia cyriacigeorgica* strain ATCC 14759. The GenBank accession number of the 16S rRNA sequence of the Iranian isolate is MF437315.

**DISCUSSION**

Nocardiosis is an acute, sub-acute, or chronic infectious disease that occurs in cutaneous, pulmonary and disseminated forms. Primary cutaneous nocardiosis manifests as cutaneous infection (cellulitis or abscess), lymphocutaneous infection (Sporotrichoid nocardiosis), or subcutaneous infection (actinomycetoma). Pleuropulmonary nocardiosis manifests as an acute, sub-acute, or chronic pneumonia, usually in immunocompromised hosts, although clinical cases have also been reported in immunocompetent hosts. Disseminated nocardiosis may involve any organ; however, lesions in the brain or meninges are most common. The first report of nocardiosis due to a novel species of the genus *Nocardia*, i.e., *Nocardia cyriacigeorgica*, was reported by Yasin et al. in 2001. The organism was isolated from a chronic bronchitis patient [2]. Since then, *Nocardia cyriacigeorgica* has been reported as a newly-emerging pathogen isolated from clinical cases in many regions of the world [5, 17].

**Table 1. Laboratory test results of the patient**

| Laboratory tests | FBS (mg dl⁻¹) | WBC (MCL⁻¹) | BUN (mg dl⁻¹) | CRP (mg l⁻¹) | ESR (mm h⁻¹) | K (mEq l⁻¹) | Na (mEq l⁻¹) | LDH (U l⁻¹) | PTT (S) | Hb (g dl⁻¹) | Cr (mg dl⁻¹) |
|-----------------|-------------|----------|-------------|----------|----------|---------|----------|----------|-------|----------|----------|
| First surgery   | 153        | 15 000   | 14          | 83       | 72       | 4.2     | 135      | 741      | 49    | 10.4     | 0.8      |
| Second surgery  | 130        | 6500     | 7           | 58       | 54       | 4.3     | 137      | –        | 34    | 11.6     | 0.7      |

*FBS, fasting blood sugar; WBC, white blood cells; BUN, blood urea nitrogen; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; K, potassium; Na, sodium; LDH, lactate dehydrogenase; PTT, partial thromboplastin time; Hb, hemoglobin; Cr, creatinine.
In a study in 2005, *Nocardia cyriacigeorgica* was isolated from a brain abscess patient with AIDS [7]. In another study in 2006, two cases of septicemia by *Nocardia cyriacigeorgica* were reported [4]. In a study by Schlaerg et al. in 2008, the first case of lung infection by *Nocardia cyriacigeorgica* was reported [5]. In 2011, Shojaei et al. reported the clinical isolation of *Nocardia cyriacigeorgica* from Iranian patients with different clinical symptoms [18]. In another study from Turkey, in 2014, *Nocardia cyriacigeorgica* was isolated from brain abscess of two patients with multiple myeloma [6].

The present study shows that *Nocardia* infection, due to lack of specific clinical manifestations, can be easily misdiagnosed as fungal or tuberculosis infection, invasive fungal disease and malignancy, as was the case in the studied Iranian patient. Isolation and identification of *Nocardia* strains is considered the only reliable diagnostic method [19].

The rare infections, such as brain abscess, due to fastidious organisms, such as *Nocardia*, in patients with underlying diseases are easily neglected in the developing countries. This is the results of inadequate microbiological experience of laboratory technicians or lack of standard microbiological protocols to consider and screen the rare fastidious microorganisms.

The presumptive identification of nocardia can be achieved on the basis of macroscopic and microscopic morphology, resistance to lysozyme and restriction profiles using the PRA-`hsp65` method. Isolates with characteristics of filamentous bacilli, forming aerial hyphae, with colonies that may be pigmented, rough and without the BstEII digestion pattern in PRA-`hsp65` method are suggestive of *Nocardia*. The PRA-`hsp65` method [13, 14] is routinely used to amplify a 440 bp gene fragment that encodes a protein of 65 kDa for mycobacteria and actinomycetes [15]. As *Nocardia* lack the BstEII restriction site, this feature can be used in the presumptive identification of the genus. Additionally, *Nocardia* PRA-`hsp65` patterns with HaeIII are different to the algorithm described by Roth et al. [16]. When necessary, sequencing of the 16S rRNA gene provides an alternative identification method for the rapid identification of *Nocardia* species of clinical significance which is even more sensitive than restriction endonuclease analysis (REA) of the HSP gene [17].

Our study underscored growing concerns over misdiagnosis of the emerging pathogens and in particular those that are hard to detect in routine hospital laboratories in a developing country. This fact, in turn, indicates requirements for quality and competence in medical laboratories in order to improve and incorporate microbiological diagnostic procedures for isolation and identification of emerging pathogens, such as mycobacteria and nocardia.

**References**

1. Nocard E. Note sur la maladie des boeufs de Guadeloupe connue sous le nom de farcin. Ann Inst Pasteur 1888;2:293–302.
2. Yassin AF, Rainey FA, Steiner U. Nocardia cyriacigeorgica sp. nov. Int J Syst Evol Microbiol 2001;51:1419–1423.
3. Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol 2003;41:4497–4501.
4. Elsayed S, Kealey A, Coffin CS, Read R, Megran D et al. Nocardia cyriacigeorgica septicemia. J Clin Microbiol 2006;44:280–282.
5. Schlaberg R, Huard RC, della-Latta P. Nocardia cyriacigeorgica, an emerging pathogen in the United States. J Clin Microbiol 2008;46:265–273.
6. Pamukcuoglu M, Emmez H, Tunccan OG, Oner AY, Cirak MY et al. Brain abscess caused by *Nocardia cyriacigeorgica* in two patients with multiple myeloma: novel agents, new spectrum of infections. Hematology 2014;19:158–162.
7. Barnaud G, Deschamps C, Manceron V, Mortier E, Laurent F et al. Brain abscess caused by *Nocardia cyriacigeorgica* in a patient with human immunodeficiency virus infection. J Clin Microbiol 2005;43:4895–4897.
8. Malincarne L, Marroni M, Farina C, Camanni G, Valente M et al. Primary brain abscess with Nocardia farcinica in an immunocompetent patient. Clin Neurol Neurosurg 2002;104:132–135.

9. Menkü A, Kurtsoy A, Tucer B, Yildiz O, Akdemir H. Nocardia brain abscess mimicking brain tumour in immunocompetent patients: report of two cases and review of the literature. Acta Neurochir 2004;146:411–414.

10. Rivière F, Billhot M, Soler C, Vaylet F, Margery J. Pulmonary nocardiosis in immunocompetent patients: can COPD be the only risk factor? Eur Respir Rev 2011;20:210–212.

11. Maraki S, Chochlidakis S, Nioti E, Tselentis Y. Primary lymphocutaneous nocardiosis in an immunocompetent patient. Ann Clin Microbiol Antimicrob 2004;3:24.

12. Brown-Elliott BA, Brown JM, Conville PS, Wallace R.J. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006;19:259–282.

13. McTaggart LR, Richardson SE, Witkowska M, Zhang SX. Phylogeny and identification of Nocardia species on the basis of multilocus sequence analysis. J Clin Microbiol 2010;48:4525–4533.

14. NCCLS. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. NCCLS document M24-A [ISBN 1-56238-500-3]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA; 2003.

15. Laurent FJ, Provost F, Boiron P. Rapid identification of clinically relevant Nocardia species to genus level by 16S rRNA gene PCR. J Clin Microbiol 2000;38:2805.

16. Roth A, Andrees S, Kroppenstedt RM, Harmsen D, Mauch H. Phylogeny of the genus Nocardia based on reassessed 16S rRNA gene sequences reveals underspeciation and division of strains classified as Nocardia asteroides into three established species and two unnamed taxons. J Clin Microbiol 2003;41:851–856.

17. Kageyama A, Hoshino Y, Yazawa K, Poonwan N, Takeshita N et al. Nocardia cyriacigeorgica is a significant pathogen responsible for nocardiosis in Japan and Thailand. Mycopathologia 2005;160:15–19.

18. Shojaei H, Hashemi A, Heidarieh P, Eshraghi S, Khosravi AR et al. Clinical isolation of Nocardia cyriacigeorgica from patients with various clinical manifestations, the first report from Iran. Med Mycol J 2011;52:39–43.

19. Lerner PI. Nocardiosis. Clin Infect Dis 1996;22:891–905.

---

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.